Provided by Tiger Fintech (Singapore) Pte. Ltd.

ProMIS Neurosciences Inc

0.5948
-0.0140-2.30%
Post-market: 0.5800-0.0148-2.49%17:22 EDT
Volume:30.41K
Turnover:18.23K
Market Cap:19.44M
PE:5.55
High:0.6330
Open:0.6020
Low:0.5575
Close:0.6088
Loading ...

Company Profile

Company Name:
ProMIS Neurosciences Inc
Exchange:
NASDAQ
Establishment Date:
2004
Employees:
8
Office Location:
1920 Yonge Street,Suite 200,Toronto,Ontario,Canada
Zip Code:
M4S 3E2
Fax:
416 847 6899
Introduction:
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Directors

Name
Position
Eugene Williams
Director,Chairman
Madge Shafmaster
Lead Independent Director
Neil Cashman
Chief Scientific Officer,Director
Josh Mandel Brehm
Director
Neil K. Warma
Director
Patrick Kirwin
Director
William Wyman
Director

Shareholders

Name
Position
Gail Farfel
Chief Executive Officer
Gavin Malenfant
Chief Operating Officer
Daniel Geffken
Chief Financial Officer
Johanne Kaplan
Chief Development Officer
Larry Altstiel
Chief Medical Officer
Neil Cashman
Chief Scientific Officer,Director